Women's Health & Pregnancy Clinical Trials

Statistical methods in women's health & pregnancy trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All women's health & pregnancy trials

790 results

• OTT15-04Independent statistical analysis of Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the…Phase 4Results postedn = 2NCT02688803
• Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2/3Results postedn = 48NCT02823080
• Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair: Complete Statistical AnalysisIndependent statistical analysis of Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00535301).Phase 4Results postedn = 75NCT00535301
• Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age: Complete Statistical AnalysisIndependent statistical analysis of Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 1NCT05345457
• Over Active Bladder Patients Having Sling Surgery: Complete Statistical AnalysisIndependent statistical analysis of Over Active Bladder Patients Having Sling Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00852696).Phase NAResults postedn = 1NCT00852696
• Overnight Pant Study for Children With Nocturnal Enuresis: Complete Statistical AnalysisIndependent statistical analysis of Overnight Pant Study for Children With Nocturnal Enuresis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05178641).Phase NAResults postedn = 32NCT05178641
• Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS: Complete Statistical AnalysisIndependent statistical analysis of Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01909141).Phase EARLY_1Results postedn = 100NCT01909141
• Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00418093).Phase 2Results postedn = 19NCT00418093
• PACERIndependent statistical analysis of Providing Adolescent Contraception in the Emergency Room: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02475980).Phase NAResults postedn = 13NCT02475980
• Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 92NCT01750073
• Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01796197).Phase 2Results postedn = 23NCT01796197
• Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 9NCT02923739
• Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 63NCT01042522
• Paclitaxel in Treating Patients With Ovarian Stromal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel in Treating Patients With Ovarian Stromal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006227).Phase 2Results postedn = 31NCT00006227
• Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 108NCT01199263
• Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 14NCT01009983
• PACSIndependent statistical analysis of Cranberry for UTI Prevention in Residents of Long Term Care Facilities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 56NCT00596635
• Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): Complete Statistical AnalysisIndependent statistical analysis of Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 521NCT01942135
• Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 162NCT02040857
• Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: Complete Statistical AnalysisIndependent statistical analysis of Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 100NCT01006629
• PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00088413).Phase 1/2Results postedn = 51NCT00088413
• Patient Centered Postpartum Contraception App: Complete Statistical AnalysisIndependent statistical analysis of Patient Centered Postpartum Contraception App: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03402217).Phase NAResults postedn = 20NCT03402217
• Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01392183).Phase 2Results postedn = 69NCT01392183
• PCMH-KDIndependent statistical analysis of Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02270515).Phase NAResults postedn = 175NCT02270515
• PCOSIndependent statistical analysis of Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 51NCT00868140
• PECS II vs. MTP for Analgesia After MRM: Complete Statistical AnalysisIndependent statistical analysis of PECS II vs. MTP for Analgesia After MRM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06187909).Phase NAResults postedn = 88NCT06187909
• Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00434330).Phase 2Results postedn = 91NCT00434330
• Pembro/Carbo/Taxol in Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembro/Carbo/Taxol in Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02549209).Phase 2Results postedn = 46NCT02549209
• Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 129NCT03260894
• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 18NCT02971761
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy:…Phase 2Results postedn = 71NCT02411656
• Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 37NCT00106002
• Pemetrexed Plus Gemcitabine in Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Plus Gemcitabine in Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00491075).Phase 2Results postedn = 16NCT00491075
• Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 12NCT03289364
• PEPSIndependent statistical analysis of Prevention of Peritonitis in Peritoneal Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01293799).Phase NAResults postedn = 713NCT01293799
• Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD): Complete Statistical AnalysisIndependent statistical analysis of Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 22NCT03812679
• Pericoital Oral Contraception With Levonorgestrel: Complete Statistical AnalysisIndependent statistical analysis of Pericoital Oral Contraception With Levonorgestrel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00922233).Phase 3Results postedn = 72NCT00922233
• Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass: Complete Statistical AnalysisIndependent statistical analysis of Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 73NCT01709227
• PERTINENCEIndependent statistical analysis of Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase EARLY_1Results postedn = 6NCT04897763
• PERUSEIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer: primary…Phase 3Results postedn = 1,436NCT01572038
• PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 57NCT01190566
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685591).Phase 1Results postedn = 49NCT03685591
• Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 17NCT03359850
• Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 6NCT02054572
• Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386): primary endpoint results, effect estimate with confidence…Phase 1Results postedn = 32NCT03311841
• Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 33NCT02011490
• Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 72NCT01132664
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 184NCT00531284
• Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 6NCT05384119
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 17NCT02901548

← All therapeutic areas